Cipla stock: Macquarie sets INR 1,730.00 target for Cipla stock

Published on 10/20/2026 at 17:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cipla posted INR 7.89 billion net income in first-quarter 2027. Cipla stock costs INR 1,324.10 on October 19, 2026, down 0.08 percent on the NSE.

Macquarie target and results

Macquarie set an INR 1,730.00 target for Cipla on October 7, 2026.
Cipla reported INR 7.89 billion net income for the first quarter of fiscal 2027.
Cipla stock stood at INR 1,324.10 on October 19, 2026, down 0.08 percent from the prior close.
Cipla is scheduled to consider second-quarter results on October 27, 2026.

Cipla, INE059A01026, Illustration mit AI erstellt.

Macquarie set a Buy target of INR 1,730.00 for Cipla on October 7, 2026, raising it from INR 1,675.00, according to Investing.com. The target stands 30.65 percent above the NSE price of INR 1,324.10 on October 19, 2026. Cipla stock last traded at INR 1,324.10 on the NSE on October 19, 2026 at 3:29 p.m. IST, down 0.08 percent from the prior close of INR 1,325.10.

Profit fell in first-quarter 2027

Cipla reported INR 70.77 billion in revenue and INR 7.89 billion in net income for the first quarter of fiscal 2027. Revenue increased from INR 65.41 billion in the fourth quarter of fiscal 2026, while net income rose from INR 5.55 billion in that preceding quarter. The figures come from Cipla's investor-relations page, which also identifies the quarter as ending June 30, 2026: Cipla.

Price sits below the yearly high

The NSE 52-week range was INR 1,165.70 to INR 1,673.00 as of October 19, 2026. The latest price was 20.86 percent below the high and 13.59 percent above the low. Trading volume was 1,387,203 shares, compared with an average volume of 1,020,615 shares.

What date matters next?

Cipla is scheduled to consider its second-quarter results on October 27, 2026, according to Univest. The upcoming report will give investors a fresh comparison with the first-quarter revenue of INR 70.77 billion and net income of INR 7.89 billion.

Comparison with peers

Cipla (NSE, INR): down 0.08 percent, P/E 31.75, market capitalization INR 1,069.7 billion.

Sun Pharmaceutical Industries (NSE, INR): down 0.90 percent, P/E 34.58, market capitalization INR 4,182.0 billion.

Dr. Reddy's Laboratories (NSE, INR): up 0.77 percent, P/E 31.29, market capitalization INR 1,035.0 billion.

Stock remains tied to results

Macquarie's INR 1,730.00 target gives the analyst view a clear numerical reference, while the first-quarter figures show revenue growth alongside higher sequential net income. The October 27 reporting date is the next scheduled company event.